X4 Pharmaceuticals to Host Virtual Seminar “Understanding Primary Immunodeficiencies” to Highlight Broadening Market Opportunities for Mavorixafor

NEXT STORY
Veru Reports Record Fiscal 2021 Full-Year Financial Results
PREV STORY
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Intravenous Infusion Pumps Global Market Report 2021: COVID-19 Growth And Change To 2030

author_avatar
NASDAQ Market News

Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy

author_avatar
NASDAQ Market News

Albireo Provides First Quarter 2018 Business Update

 First patient enrolled in Phase 3 trial of IBAT inhibitor A4250 in PFIC   Elobixibat ...

author_avatar
NASDAQ Market News